Resolution Economics LLC

11/19/2026 | Press release | Distributed by Public on 11/19/2026 17:32

Key Takeaways from the 27th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress

Key Takeaways from the 27th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress

General Counsel, outside counsel, compliance executives, representatives of regulatory bodies and forensic practitioners met and discussed an array of issues at the 27th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress. The following highlights a few key topics.

Artificial Intelligence (AI) in the Life Sciences Industry Update

  • Companies are challenged to evaluate AI Bias and how to solve for any identified bias
  • AI adoption is outpacing governance. 74% of pharmaceutical and biotech companies use AI, but only 14% report comprehensive governance frameworks
  • Attendees and speakers discussed a shift from AI that compliance teams "chat with" to AI embedded in business workflows, including agentic tools that can:
    • Run routine checks and flag issues before a decision is final, moving away from sample-based review
    • Escalate exceptions to a human reviewer with a documented audit trail
  • 2026 case law held that consumer AI use can waive privilege, so privileged materials should be limited to enterprise tools

Regulatory Update

  • False Claims Act activity hit a record high in FY 2025 with $6.8B recovered, over $5.7B from healthcare
  • Department of Justice's (DOJ) Fraud Oversight through Careful Use of Statistics (FOCUS) initiative invites data miners to submit fraud leads. Since 2024 data miners drive roughly 45% of new qui tams
  • Medical devices are a DOJ and Health and Human Services (HHS) priority, including sales-based consulting "royalties" and cybersecurity misrepresentations

Compliance Program Update

  • Speaker programs and consulting services remain top kickback risks. Key controls include repeat-attendance caps, fair market value and deliverables tracking, and monitoring for outliers in healthcare professional (HCP) spend
  • Documentation is critical. Training logs and attestations are what regulators and Corporate Integrity Agreement (CIA) auditors requests first

Patient Assistance & Market Access Programs

  • Key risk considerations for patient assistance, hub and market access management:
    • Keep foundations independent and do not calibrate donations to product use
    • Restrict commercial access to foundation and patient-specific data
    • Verify that paid services are performed and that fees don't vary with volume
    • Free nursing or reimbursement support and gamified patient apps may be viewed as inducements

For further information and discussion on these points or other matters facing the Life Sciences and Healthcare Industries please contact us.

Facebook
Twitter
LinkedIn
WhatsApp
You are here:
  1. Home
  2. All
  3. Key Takeaways from the 27th…

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name * Email * Website

Save my name, email, and website in this browser for the next time I comment.

Post comment

Resolution Economics LLC published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2026 at 23:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]